Mekonos announces partnership with Opentrons’ subsidiary Neochromosome

Our portfolio company #1 Mekonos has announced an exciting partnership to build designer chromosomes as part of the next generation of cell therapy. These therapies are the key to personalised medicine, which could lead to significantly improved health outcomes for patients. Opentrons and Neochromosome are both important players in this space so this partnership is very exciting, starting in the San Francisco Bay area in January 2022.

Read more here: